Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide 2.4 mg) does not simply switch off. Most people find that weight loss slows considerably after the first few months, and some notice the scales barely moving at all after six to twelve months — but a plateau is not the same as the medicine failing. Understanding why progress stalls, and what can be done about it, changes everything about how to respond. These are prescription-only medicines, and any changes to treatment should be discussed with your prescriber.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You've been taking Wegovy for a while. Early on, the weeks felt different: appetite quieter, portions smaller, energy shifting. Then, gradually, the number on the scale stopped changing. It can feel like a betrayal, especially when you've been consistent. That frustration is completely understandable, and it's one of the most common questions prescribers hear.
What's actually happening is a physiological process that occurs with virtually every effective weight-loss intervention: adaptive thermogenesis. As body weight falls, the body reduces its energy expenditure to defend a new lower weight. Hunger signals can also partially recover over time as the system recalibrates. The medicine is still working (it is still activating GLP-1 receptors, slowing gastric emptying, and reducing appetite signals) but the body has adjusted around it. The how semaglutide works page goes into the mechanism in more detail if you want the biology explained clearly.
This pattern is well-documented. The STEP 1 trial, published in the New England Journal of Medicine, showed average weight loss of around 15% over 68 weeks, with the steepest drop in the first twenty or so weeks and a levelling-off thereafter. A plateau late in treatment is consistent with what the trial itself recorded, not a sign something has gone wrong.
There is a distinction worth making here. A plateau is not the same as the medicine stopping. Wegovy can stop working in a more meaningful sense in a few specific situations: if doses are missed regularly, if the titration schedule was not completed (meaning the therapeutic dose was never properly reached), if significant changes to diet have quietly crept in, or if a medical condition affecting metabolism is present and unaddressed.
There is also individual variation in response. A minority of people are classified as low responders, those who reach the maintenance dose and sustain it for several months without achieving at least 5% weight loss. NICE's guidance on semaglutide notes that continuing treatment should be reviewed if less than 5% weight loss is seen after six months on the maintenance dose. If you want to understand more about whether Wegovy stops working after a while and why that happens for some people, the picture is more nuanced than a simple yes or no. This is not a failure of willpower; it reflects genuine biological differences in how people respond to GLP-1 receptor agonists.
If you are wondering whether Wegovy has stopped working for you specifically, the answer will depend on how long you have been at your current dose, what your overall loss looks like from the start, and what other factors might be in play. That conversation belongs with a prescriber, not a forum.
One thing the evidence is clear on: stopping Wegovy tends to reverse much of the progress made. Studies show that a significant proportion of weight lost is regained within a year of stopping, even when lifestyle changes were made during treatment. The NHS medicines page for semaglutide outlines this honestly, framing Wegovy as a longer-term medicine rather than a finite course.
If weight loss has genuinely plateued and you are already at the maintenance dose, the options depend on clinical assessment. Some people benefit from a structured review of eating patterns and activity levels, since the medicine works best alongside both. Others may not have reached their highest tolerated dose yet. And for some, the question becomes whether a different treatment (such as tirzepatide, which acts on two gut-hormone pathways rather than one) might produce a better response. You can read about other weight-loss treatment options to understand what alternatives exist.
There is also the question of dose accuracy: if injections are not being given consistently to the same sites, or technique has drifted, absorption can vary. A prescriber review covers all of this systematically. If you have specific concerns about what to do if Wegovy stops working for you, that page covers the practical steps in detail.
The reasons semaglutide can stop working are broader than most people realise, and worth reading before drawing conclusions. It is also useful to understand what Wegovy starting to work actually looks like, because some people expect changes that do not reflect how the medicine behaves in practice. At nume, our prescribers review every repeat order, so if something has shifted in your response, that is the right moment to raise it. Speak to our prescribers if you want a clinical eye on where you are in treatment and what makes sense next.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.